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An estimated 30 - 40% of HIV-infected patients are likely to develop cancer during the progression of their disease. The 
occurrence of malignancy among these patients represents a difficult challenge in their care. Kaposi’s sarcoma (KS) – currently 
the most common tumour observed with an estimated incidence of 15 - 20% – represents the first manifestation of AIDS in 
30 - 40% of patients. Any organ may be involved, but the gastrointestinal tract and lung remain the most frequently involved 
locations. The case described here presented a clinical and ethical dilemma where visceral KS, pregnancy and medical 
complications required multi-disciplinary management.
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A 24-year-old woman was referred to the 
Division of Oncology at a large academic 
hospital. She had presented recently at a 
local hospital with a history of progressive 
shortness of breath, and had received 
treatment for atypical, multilobular pneumonia. She was 
diagnosed with HIV in 2009 when she presented with severe 
mucocutaneous Kaposi’s sarcoma (KS) as her AIDS-defining 
disease. She was pregnant at the time of her initial diagnosis, 
and received 4 cycles of bleomycin/vincristine chemotherapy 
after delivering a healthy term infant. This was followed by an 
additional 14 cycles of chemotherapy, which was discontinued 
when her KS lesions demonstrated a good clinical response. 
She returned 6 months later with KS progression and was 
re-challenged with the ABV regime (doxorubicin, bleomycin 
and vincristine) for 6 cycles. She reached the tolerance dose 
of bleomycin, and chemotherapy was discontinued. A large 
lesion behind her left earlobe was treated with a short course 
of palliative external beam radiotherapy (EBRT). 
In February 2012, KS progression was visible, this time 
involving the genital area, mouth and lymph nodes. Again, she 
was challenged with combination chemotherapy containing 
doxorubicin and vincristine for 4 cycles, with no clinical 
benefit, and palliative EBRT was offered to problematic lesions 
of the vulva and left foot.
In June 2012 she was admitted to the high-care unit 
with a 2-month history of progressive, grade IV dyspnoea, 
intermittent cough, and bleeding from a palatial KS lesion in 
her mouth. She was 27 weeks pregnant and had been treated at 
a local hospital for pneumonia and started on anti-tuberculosis 
(TB) treatment 2 weeks earlier.
On inspection, the patient was acutely ill with signs of a 
hyper-dynamic circulation and peripheral oedema. Physical 
examination revealed bilateral coarse crepitations, wheezes 
and the use of accessory respiratory muscles. A large, bleeding, 
nodular KS lesion was observed, involving most of the hard 
palate and oropharynx. Abnormal laboratory studies revealed 
reduced haemoglobin (7.8 g/dl), raised C-reactive protein 
(75.0 mg/l), low albumin (26 g/l), raised fibrinogen (4.4 g/l), 
raised D-dimer (1.34 mg/l) and raised lactate dehydrogenase 
(368 U/l) levels and a low CD4 count (137 cells/µl). A standard 
blood culture was negative. A routine chest X-ray (CXR) 
revealed bilateral opacities infiltrating predominantly the 
perihilar peribronchovascular interstitium of both lungs (Fig. 1).
According to the AIDS Clinical Trials Group (ACTG) staging 
system, the patient was classified as a poor-risk stage IV (T1,I1,S1) 
Fig. 1. Chest X-ray showing bilateral KS opacities infiltrating pre-
dominantly the perihilar peribronchovascular interstitium (these 
may often be mistaken for opportunistic infections).
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HIV/AIDS patient with a problem list of: (i) 
HIV-infected since 2009, receiving antiretroviral 
therapy (ART); (ii) CD4 count of 137 cells/µl; 
(iii) 2 weeks of anti-TB treatment; (iv) KS since 
2009 (for which she received multiple cycles of 
chemotherapy and palliative EBRT); (v) current 
presentation of bilateral, multi-lobular infiltrates 
on a CXR with a high index of suspicion of 
lung KS involvement; (vi) early signs of early 
diffuse intravascular coagulation (DIC); and (vii) 
pregnancy (28 weeks).
Management
A multi-disciplinary team (MDT), comprising a 
high-care medical team, oncologist, obstetrician 
and the HIV/infectious diseases personnel, was 
required for optimal management. 
Intravenous antibiotic therapy (clarithro-
mycin), concurrent ART (tenofovir, efavirenz 
and lamivudine) and anti-TB (rifafour) 
supportive treatment were continued, with the 
addition of trimetroprim-sulfamethoxazole 
as Pneumocystis jyroveci prophylaxis, as the 
patient's current CD4 count was <200 cells/ µl. 
Continuous positive airway pressure (CPAP) 
was required as she became entirely dependent 
on the support system to maintain breathing. 
Sub-cutaneous heparin was administered dur-
ing her hospital stay. 
On day two post admission, she reported 
no fetal activity and an obstetric consult 
confirmed an intra-uterine death. She went 
into spontaneous labour and delivered a 
premature, stillborn microcephalic fetus 
(weighing 1 380 g). 
Her bleeding KS mouth lesion was controlled 
with adrenaline gauze. Due to her poor 
perform ance status, low CD4 count, resistant 
KS, extent of KS disease and poor prognosis, 
no active chemotherapy management was 
offered. She died 3 hours post delivery due to 
extensive KS and respiratory failure.
Discussion
In sub-Saharan Africa, where many patients 
access ART with advanced HIV disease, AIDS-
related KS presents with a high tumour burden 
and rapid disease progression, resulting in a 
life expectancy of <6 months.[1] KS involving 
the lung presents as shortness of breath, fever, 
cough, chest pain and haemoptysis, or as an 
incidental nding on a CXR.[2]
A prognostic index can guide therapeutic 
options for AIDS-related KS, including: immune 
status (CD4 count); patient age; AIDS-defining 
disease on presentation; and the presence of 
co-morbid conditions. Patients with a favourable 
prognostic index can be treated initially with 
ART alone. Systemic chemotherapy is warranted 
in advanced, systemic or rapid, progressive KS 
disease. Several chemotherapeutic agents – 
e.g. bleomycin, vincristine, vinblastine, and an 
anthracycline (doxorubicin) – have activity in 
the treatment of KS, but in the developed world, 
liposomal doxorubicin and a taxane group 
constitute the backbone of current systemic 
chemotherapy against KS.[1,3,4] In all cases, an 
objective response of 70 - 80% can be obtained 
with various combinations of chemotherapy. 
Partial responses and clinical benefit are 
frequently observed, but relapses often occur 
when treatment is stopped.[3,5]
Our patient initially received a combination 
of bleomycin and vincristine, and was 
re-challenged with the ABV combination 
when her KS progressed. Unfortunately, 
treatment with systemic chemotherapy comes 
at a cost: both bleomycin and doxorubicin have 
a maximum tolerable dose before long-term 
complications become evident. In addition, 
bleomycin may induce alveolitis and pulmonary 
fibrosis, and there is evidence of accelerated 
pulmonary dysfunction in lung KS patients who 
received bleomycin.[6] Doxorubicin is associated 
with irreversible cardiac damage (congestive 
heart failure and cardiomyopathy) when the 
maximum dose of ≥450 mg/m2 is exceeded. 
The patient described here had reached the 
maximum tolerable dose of both bleomycin 
and doxorubicin. She developed progressive 
KS during the last 4 cycles of doxorubicin-
based therapy; therefore, it may be postulated 
that her KS became resistant to anthracycline 
chemotherapy. As both liposomal doxorubicin 
and the taxane drugs are not available in 
the public healthcare sector, second-line 
chemotherapy could not be offered.
The incidence of pregnancy-associated 
malignancy ranges from 0.02 - 0.10%; the 
most common malignancies diagnosed during 
pregnancy are gynaecological, haemato logical 
and skin cancers (malignant melanoma). 
Malignancies in pregnancy present the MDT 
with an ethical conflict between the optimum 
management of the cancer and preservation 
of the pregnancy.[7] For most of these cancers, 
chemotherapy is necessary to achieve a 
cure or efficient palliation of cancer-related 
symptoms. The consequence of chemotherapy 
and/or EBRT during the first trimester is high 
(congenital malformation or spontaneous 
abortion), and termination of pregnancy v. 
delayed treatment should be discussed with 
the patient. Chemotherapy treatment during 
the second and third trimesters follows 
the standard chemotherapy guidelines, but 
delivery should be timed during a non-
neutropaenic period and care should be taken 
to time the last cycle of treatment at 32 weeks 
of gestation. However, patients remain at high 
risk and this warrants careful monitoring.[8]
The patient described in this case presented 
with a 28-week pregnancy, but had received 
chemotherapy and EBRT during the first 
trimester when she was unaware of her 
pregnant status. This resulted in an intra-
uterine death and early clinical DIC that 
concluded in a spontaneous delivery, probably 
due to maternal hypoxia and the abnormal 
fetus (microcephaly). Few studies are available 
concerning in utero chemotherapy-exposed 
neonates. In one study, the mean gestational 
age at delivery was 35.8 weeks, the mean birth 
weight was 2  647 g, and 4% of infants were 
born with a congenital abnormality.[8,9]
Conclusion 
is case highlights the clinical complications 
and ethical dilemma associated with advanced 
KS in pregnancy. e MDT plays an important 
role in securing optimal care for patients 
with advanced HIV disease, malignancy and 
associated pregnancy.  
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